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Purpose: To evaluate the outcome of a combined photodynamic therapy and intravitreal injection of bevacizumab in 
choroidal neovascularization secondary to age-related macular degeneration. 
Methods: Photodynamic therapy (PDT) was administered to 28 eyes followed by 3 consecutive bevacizumab 
injections. Patients were followed-up for more than 12 months. At baseline, 1, 3, 6, and 12 months post PDT, vis-
ual acuity (VA) and central macular thickness were measured using optical coherence tomography. 
Results: The mean VA was significantly improved from logarithm of the minimal angle of resolution 0.86 at baseline 
to 0.69 at 1 month (p = 0.011), 0.63 at 3 months (p = 0.003), 0.64 at 6 months (p = 0.004) and 0.60 at 12 months 
(p < 0.001). Central macular thickness decreased significantly from 328.3 μm at baseline to 230.0 μm at 6 months 
and 229.9 μm at 1 year (p < 0.001). Reinjection mean number was 0.4 for 6 months and 0.8 for 12 months. By 1 
year, retreatment was performed in 10 eyes (36%).
Conclusions: PDT combined with three consecutive intraviteal bevacizumab injections was effective in improving 
VA and reducing central macular thickness.
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Photodynamic therapy (PDT) with verteporfin (Visudyne; 
Novartis Pharma AG, Basel, Switzerland) has been shown to 
reduce the risk of moderate and severe vision loss in pa-
tients with choroidal neovascularization (CNV) secondary 
to age-related macular degeneration (AMD). However, PDT 
rarely achieved visual improvement [1-3]. Choroidal hypo-
perfusion has been reported as a common side-effect after 
PDT [4]. Choroidal ischemia and its associated inflammation 
induce production of vascular endothelial growth factor 
(VEGF), which may lead to recurrence or new incidence of 
CNV [5,6]. To manage recurrence, it is necessary to repeat 
PDT, which may result in choroid or retina atrophy and re-
duce visual function [7]. 
Bevacizumab, a recombinant full-length humanized mon-
oclonal antibody that binds all VEGF isoforms, was origi-
nally approved for treatment of metastatic carcinoma of the 
colon and rectum; however, it has been used as an off-label 
intravitreal treatment for CNV [8,9]. Several uncontrolled 
studies and case series have shown anatomical improvement 
and moderate vision gain when bevacizumab was used as a 
monotherapy [8-12]. However, repeated intravitreal in-
jections are subject to the risk of complications, discomfort 
for the patient, and increased health care expense [13-16]. 
As CNV is a multi-factorial disease process, it was hy-
pothesized that a combination therapy of different mecha-
nisms of action would have additive or complementary 
treatment effects, and possibly result in the improvement of 
functional outcome as well as reduce the need for frequent 
retreatment [17]. Combination therapy has many options re-
garding sequence, interval, and number of each treatment 
given. Based on the report that the choroidal hypofluor-Korean J Ophthalmol Vol.25, No.4, 2011
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Table 1. Baseline demographic and lesion characteristics 
for patients with more than 6 months follow up
Characteristic
No. of patients     28
Age (yr)  67.8 (55-82)
Gender (%)
Male      18 (64)
Female      10 (36)
Visual acuity (Snellen)    0.2 (0.02-0.8)
Visual acuity (logMAR)  0.86 (±0.49)
Central subfield retinal thickness (μm) 328.3 (180-570)
Lesion type (%)
Predominant classic       8 (29)
Minimal classic       4 (14)
Occult without classic     16 (57)
Greatest linear diameter (μm) 2,840 (900-5,220)
logMAR = logarithm of the minimum angle of resolution.
escence was found in indocyanine green (ICG) angiography 
for 3 months after PDT [4] and that the main functional im-
provement was achieved after 3 consecutive ranibizumab in-
jections [14,15,18,19], we conducted combined PDT and 3 
consecutive intravitreal bevacizumab injections as treatment 
for patients with CNV secondary to AMD. This study was 
conducted to determine if this combination could achieve vi-
sion improvement and reduce the number and frequency of 
retreatment. 
Materials and Methods
We retrospectively reviewed consecutive cases of exuda-
tive AMD that were treated with combined therapy of 
full-fluence PDT and 3 consecutive intravitreal injections of 
1.25 mg bevacizumab (Avastin; Genentech, South San 
Francisco, CA, USA) that were followed up for more than 1 
year. All institutional review boards approved the off-label 
usage of bevacizumab and all patients signed an informed 
consent.
All patients were diagnosed with CNV due to wet AMD. 
The CNV diagnosis was confirmed by fundus examinations, 
fluorescein angiography (FA), and ICG angiography. 
Patients with a history of previous CNV treatment, or evi-
dence of other disease that may cause CNV including my-
opic degeneration and angioid streaks, were excluded. Eyes 
with polypoidal choroidal vasculopathy were also excluded. 
PDT was performed according to the Treatment of 
Age-Related Macular Degeneration with Photodynamic 
Therapy Study (TAP) regimen [20]. Greatest lesion diameter 
(GLD) was decided based on FA findings. Laser fluence and 
verteporfin (Visudyne, Novartis, Basel, Switzerland) doses 
were not reduced. Three consecutive intravitreal injections 
of 1.25 mg bevacizumab were performed within 3 days, at 1 
month, and 2 months post PDT. 
Best corrected visual acuity (VA) measurement, fundus 
examination, and optical coherence tomography (OCT; 
Stratus OCT, Carl Zeiss Meditec Inc., Dublin, CA, USA) 
were performed at each visit. OCT scans were performed us-
ing the Fast macular thickness map protocol. Scans with sig-
nal strength of 6 or higher were used for analysis. If a radial 
scan contained a segmentation algorithm error in the central 
1 mm, it was excluded from map calculation. FA was per-
formed to assess lesion activity when clinically indicated. 
Additional treatment was decided at the physician’s dis-
cretion based on previous reports [1-3,21]. Retreatment of ei-
ther PDT or intravitreal bevacizumab were performed in the 
following cases: when a VA loss of at least 1 line with OCT 
evidence of fluid in the macula occurred, when an increase in 
central subfield macular thickness of at least 100 μm was 
present, when a new area of classic CNV with macular hem-
orrhage in FA developed, or when persistent subretinal or in-
traretinal fluid on OCT occurred.
VA was measured using a standard Snellen chart and was 
converted to logarithm of the minimum angle of resolution 
(logMAR) for statistical analysis. Improved or worsened VA 
was defined as a change of 0.3 or more in the logMAR score. 
The main outcome measures were changes in VA and central 
subfield macular thickness during the 12-month follow-up 
period. The occurrences of retreatment were also evaluated. 
Statistical analysis was performed with SPSS ver. 13.0 
(SPSS Inc., Chicago, IL, USA).
Results
Twenty-eight eyes from 28 consecutive patients (18 men 
and 10 women) were included in this study. Baseline charac-
teristics are summarized in Table 1. The mean patient age 
was 67.8 years and the patients were followed up for an aver-
age of 17.2 months (range, 12 to 33 months). The type of 
CNV was predominantly classic in 8 eyes, minimal classic in 
4 eyes, and occult in 16 eyes. The mean GLD was 2,840 μm 
(±1,033; range, 900 to 5,220).
 VA (logMAR) was 0.86 at baseline, 0.69 at 1 month (p = 
0.011), 0.63 at 3 months (p = 0.003), 0.64 at 6 months (p = 
0.004) and 0.60 at 1 year (p < 0.001) (Fig. 1A). The differ-
ence between baseline and every other visit was statistically 
significant (Wilcoxon signed rank sum test). VA improved by 
3 lines or more in 13 eyes (46.4%) at 6 months and in 12 eyes 
(42.9%) at 1 year (Table 2). VA decreased by 3 lines or more 
in 2 eyes (7.1%) at 6 months and 1 eye (3.6%) at 1 year. GLD 
significantly correlated with VA at 1 year (p < 0.001), but not 
with baseline acuity or acuity change (Spearman’s ranked 
correlation). The mean central subfield macular thickness de-
creased significantly from 328.3 μm at baseline to 230.0 μm at 
6 months and 229.9 μm at 1 year (p < 0.001) (Fig. 1B). 
In the 8 patients with predominantly classic lesions, VA 
changed from a logMAR of 1.15 at baseline to 0.73 at 6 
months and 0.71 at 1 year. VA did not change in 4 eyes (50%) 
and improved in 4 eyes (50%). In the 16 eyes with occult 
CNV, VA was 0.79 at baseline, 0.69 at 6 months, and 0.64 at HW Kim, et al. Combined Treatment for CNV Secondary to ARMD
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A B
Fig. 1. Mean visual acuity (A) and mean central retinal thickness on optical coherence tomography (B) before and at 12 months after combined 
treatment of photodynamic therapy and 3 consecutive monthly bevacizumab injections. logMAR = logarithm of the minimal angle of 
resolution. 
*p < 0.05, Wilcoxon signed rank sum test. 
Table 2. Visual acuity changes after combined treatment of photodynamic therapy and 3 consecutive monthly bevacizumab 
injections for choroidal neovascularization complicated with age-related macular degeneration 
Baseline 1 mon 3 mon 6 mon 12 mon
Mean visual acuity (logMAR) 0.86 0.71 0.63 0.64 0.60
Visual acuity distribution (eyes)
<20 / 200 7 5 6 6 6
20 / 200-20 / 40 18 16 8 9 9
≥20 / 40 3 7 14 13 13
Visual acuity changes (eyes)
≥3 line decrease 3 2 2 1
Change of 2 lines or less  16 14 13 15
≥3 line improvement 9 12 13 12
logMAR = logarithm of the minimum angle of resolution.
A B
Fig. 2. (A) Kaplan-Meyer analysis represents the number of eyes that did not require additional treatment after combined photodynamic ther-
apy and 3 consecutive monthly bevacizumab injections. (B) Numbers of retreatment from 3 to 12 months.
1 year. VA improved in 5 eyes (31%) and decreased in 1 eye 
(3%). The difference in visual improvement among lesion type 
was not statistically significant (Kruskal-Wallis test, p > 0.05).
The mean number for reinjection was 0.4 at 6 months and 
0.8 at 12 months. At 6 months, 10 injections of bev-
acizumab and 2 PDT were performed in 7 eyes as additional 
treatments (23.3%) (Figs. 2 and 3). Between months 7 and 
12, 6 eyes (20.0%) required 13 injections and 1 PDT (Fig. 
2). Overall, retreatment was required in 10 eyes (33.3%), 
and 18 eyes (56.7%) did not require additional anti-VEGF 
injections or PDT other than the initial combined treatment 
for 12 months of follow up (Figs. 2 and 4). There were no 
intravitreal injection-related complications such as endoph-
thalmitis, glaucoma, retinal detachment, uveitis, or other 
non-ocular complications. Korean J Ophthalmol Vol.25, No.4, 2011
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Fig. 3. (A) A 59-year old woman with a visual acuity (VA) score of 0.02 had classic choroidal neovascularization revealed in early (B) and late 
phase (C) fluorescein angiography. At 5 months after combined photodynamic therapy and 3 monthly bevacizumab injections a new subretinal 
hemorrhage developed. (E) At 1 year, VA improved to 0.6 after two additional bevacizumab injections. (F) Optical coherence tomography 
shows choroidal neovascularization and associated subretinal fluid before treatment. (G) Subretinal fluid resolved completely with combined 
treatment and two injections for 1 year. 
Discussion
Although PDT monotherapy had better functional results 
than the sham treatment, patients had an average loss of 2.2 
and 3.1 lines of vision in the previous TAP and Verteporfin in 
Photodynamic Therapy studies, respectively [1,20]. In the 
verteporfin treatment group of the anti-VEGF antibody for the 
treatment of predominantly classic choroidal neovascularisation 
in AMD (ANCHOR) study, the mean VA decrease was 9.5 
letters [15]. PDT with verteporfin is relatively selective for 
CNV; however, it may cause ischemia of the normal choroi-
dal vessels [4]. Following reactive hypoxia, proinflammatory 
cytokine and VEGF can promote recurrence of CNV. The re-
peated PDT insults may result in RPE and choroidal atrophy. 
To improve the functional results of PDT, it is important to 
control inflammation related to PDT. This is supported by 
several reports that have shown a beneficial effect on vision 
from PDT combined with triamcinolone acetonide intra-
vitreal administration [22-24].
Anti-VEGF therapy with ranibizumab has shown better 
visual outcomes in prospective multicenter studies. The 
MARINA study, in which patients received intravitreal in-
jections of ranibizumab monthly for 2 years, showed a mean 
improvement in VA of 6.5 and 7.2 ETDRS letters for the 
0.3mg and 0.5mg ranibizumab doses, respectively [14]. 
However, these results were based on frequent injections at 
fixed intervals every month, which increases the risk of en-
dophthalmitis or retinal detachment complications as well as 
increasing economic burden. Therefore, many studies have 
been conducted to decrease the number of intravitreal in-
jections without deterioration of the functional outcomes of 
anti-VEGF treatment.
The Prospective OCT Imaging of Patients with Neovascular 
AMD Treated with Intraocular Ranibizumab (PrONTO) 
study involved 3 scheduled ranibizumab injections and then 
as required based on clinical findings. The mean improve-
ment in VA was 9.3 Early Treatment Diabetic Retinopathy 
Study (ETDRS) letters with an average of 5.6 injections over 
12 months, and 11.1 letters with 9.9 injections over 24 
months [25,26]. Improvement in the logMAR score (0.26) in 
this study is comparable to the PrONTO study.
Inhibition of VEGF suppresses the development and main-
tenance of neovascularization but is less efficient on estab-
lished neovascularization, which is assumed to be the cause 
of the high recurrence rate after anti-VEGF treatment 
[17,18]. In contrast, PDT with verteporfin treatment was 
shown to induce occlusion of mature new vessels, which are 
not inhibited by anti-VEGF agents [27]. Therefore, the com-HW Kim, et al. Combined Treatment for CNV Secondary to ARMD
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Fig. 4. (A) A 76-year old man presented with age-related macular degeneration in the right eye. Posterior subcapsular opacity blurs the posteri-
or pole. The visual acuity (VA) score was 0.2. Fluorescein angiography of the early (B) and late (C) phase shows occult choroidal neo-
vascularization with active leakage. (D) After combined treatment of photodynamic therapy and 3 monthly bevacizumab injections, VA in-
creased to 0.6. (E) At 1 year, he underwent cataract surgery. VA remained at 0.6 without retreatment. Optical coherence tomography at pre-
sentation (F) shows subretinal fluid, which resolved 3 months after the combined treatment (G).
bination of PDT with anti-angiogenic agents is expected to 
have some additive benefits related to VA improvement and 
reduction of treatment rates.
In the first prospective multicenter trial of combination 
PDT and ranibizumab treatment (the ranibizumab combined 
with verteporfin photodynamic therapy in neovascular age 
related macular degeneration [FOCUS] study), PDT was 
performed at baseline and then as required, and monthly rani-
bizumab injections were administered [28]. Although the 
combined treatment showed better visual improvements than 
PDT alone, the injection rate was not reduced. 
Several studies have reported the results of PDT combined 
with a single intravitreal injection of anti-VEGF. Smith et al. 
suggested that the mean improvement in VA was 1.57 lines 
by a single intravitreal injection with bevacizumab followed 
by PDT at the final 12 month follow up [29]. Mean numbers 
of retreatment per eye were 0.57 during the 12 month follow 
up. Navea et al treated 63 patients using bevacizumab intra-
vitreal injection followed by PDT for 12 months [16]. The 
mean numbers for additional PDT and additive bevacizumab 
injections per patient were 0.46 and 1.0, respectively. No ad-
ditional treatment for recurrence was required in 46% of the 
cases. Although the results of the above studies cannot be 
compared directly with the MARINA and ANCHOR trials, 
the combined therapy seems promising as a method to reduce 
the need for retreatment.
In the current study, eyes with exudative AMD were treat-
ed using 3 consecutive intravitreal bevacizumab injections 
following PDT. Our protocol was based on the following 
aspects. First, according to the MARINA and ANCHOR 
studies, VA was most improved after the first 3 monthly in-
travitreal ranibizumab injections [14,15,18,19]. Second, cho-
roidal hypofluorescence may be noted in ICG angiography 
for 3 months after PDT. Using this protocol, we expected to 
achieve more functional improvement and less retreatment. 
Compared to the results of studies using PDT combined 
with a single injection, our protocol resulted in a reduced 
number of injections. However, 3 consecutive monthly in-
jections did not eliminate recurrence, and considering the 
number of the basic treatments, more injections were per-
formed in the current study. 
Regarding the functional results, VA was maintained or 
improved in 96.4% of eyes at 1 year. However, the number of 
eyes with poor VA (less than 20 / 200) did not change during 
follow up (Table 2). Final VA significantly correlated with 
GLD, which represents lesion size. These results indicate 
that it would be difficult to restore VA with the combined 
treatment in cases where CNV had already enlarged and vis-
ual function had severely deteriorated. 
In spite of choroidal hypofluorescence in ICG after PDT, Korean J Ophthalmol Vol.25, No.4, 2011
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clinically significant choroidal ischemia is not uncommon 
[4,6,30]. As VEGF may have a physiologic role in prevent-
ing significant infarction and recovering normal choroidal 
perfusion as well as inducing pathologic CNV, reduced flu-
ence could result in better outcomes in combination treatment 
with PDT and anti-VEGF. In the phase 2 Reduced Fluence 
Visudyne PDT Combined with Anti-VEGF and Dexamethasone 
in Combination for AMD Lesions (RADICAL) study, the triple 
therapy showed superior VA and decreased treatment frequency 
compared with anti-VEGF monotherapy [31]. 
In conclusion, the combination treatment of PDT and 3 
consecutive anti-VEGF injections resulted in improved visu-
al function and macular anatomy for 1 year. The correlation 
of GLD with VA at 1 year suggests that early diagnosis and 
intervention is an important factor for visual prognosis. This 
study was limited by its retrospective design and small sam-
ple size without controls. Further studies on various treat-
ment combinations with reduced fluence PDT and anti- 
VEGF are necessary. Moreover, further studies regarding re-
treatment criteria and methods with larger controlled trials 
are required to design the optimal treatment guide for neo-
vascular AMD.
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